The cyclooxygenase-2 inhibitor celecoxib effectively suppresses the development of non-melanoma skin cancers: results of a phase II/III clinical trial

被引：0
|
作者：
Elmets, C. A. [1 ]
Viner, J. L. [7 ]
Pentland, A. P. [9 ]
Cantrell, W. [1 ]
Bailey, H. [2 ]
Kang, S. [3 ]
Linden, K. G. [4 ]
Heffernan, M. [5 ]
Madeleine, D. [6 ]
Elewski, B. [1 ]
Umar, A. [7 ]
Lin, H. [1 ]
Bell, W. [1 ]
Gordon, G. [8 ]
机构：
[1] Univ Alabama, Birmingham, AL USA
[2] Univ Wisconsin, Madison, WI USA
[3] Univ Michigan, Ann Arbor, MI 48109 USA
[4] Univ Calif Irvine, Irvine, CA USA
[5] Washington Univ, St Louis, MO USA
[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[7] NCI, Bethesda, MD 20892 USA
[8] GD Searle Inc, Skokie, IL USA
[9] Univ Rochester, Rochester, NY USA
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2009年 / 129卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
325
引用
收藏
页码：S55 / S55
页数：1
相关论文
共 50 条
  • [21] Celecoxib for the treatment of non muscle invasive bladder cancer. Results from the first phase II clinical trial
    Pagliarulo, V.
    Martines, I.
    Telari, S.
    Ancona, P.
    Trerotoli, P.
    Albo, G.
    Pagliarulo, A.
    EUROPEAN UROLOGY SUPPLEMENTS, 2008, 7 (03) : 299 - 299
  • [22] Cyclooxygenase-2 Genetic Variants Are Predictive of Patient Benefit: Biomarker Analyses from a Randomized Phase II Trial Evaluating Concurrent Chemoradiotherapy with or Without Celecoxib in Unresectable Stage III Non-Small Cell Lung Cancer
    Bi, N.
    Liang, J.
    Zhou, Z.
    Chen, D.
    Fu, Z.
    Yang, X.
    Hui, Z.
    Feng, Q.
    Xiao, Z.
    Lv, J.
    Wang, X.
    Zhang, T.
    Wang, X.
    Deng, L.
    Wang, W.
    Wang, J.
    Ran, J.
    Wang, L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : S16 - S17
  • [23] Safety and Efficacy of RP1+Nivolumab in Patients with Non-Melanoma Skin Cancer of the Head and Neck: Results From IGNYTE Phase 1/2 Multi-Cohort Clinical Trial
    Niu, J.
    Milhem, M.
    Vanderwalde, A. M.
    Chmielowski, B.
    Beasley, G.
    Samson, A.
    Sacco, J. J.
    Bowles, T.
    Jew, T.
    He, S.
    Raza, S.
    Harrington, K.
    Middleton, M. R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 112 (05): : E8 - E9
  • [24] Plasma LOX-Products and Monocyte Signaling Is Reduced by Adjunctive Cyclooxygenase-2 Inhibitor in a Phase I Clinical Trial of Tuberculosis Patients
    Jontvedt Jorgensen, Marthe
    Nore, Kristin G.
    Aass, Hans Christian D.
    Layre, Emilie
    Nigou, Jerome
    Mortensen, Rasmus
    Tasken, Kjetil
    Kvale, Dag
    Jenum, Synne
    Tonby, Kristian
    Dyrhol-Riise, Anne Ma
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2021, 11
  • [25] Epigallocatechin gallate in the chemoprevention of non-melanoma skin cancer, with biomarker studies of actinic keratoses, sun-damaged, and non sun-damaged skin: Results of a clinical trial.
    Linden, KG
    Carpenter, PM
    McLaren, CE
    Barr, RJ
    Arain, S
    Hite, P
    Sun, JD
    Li, KT
    Viner, JL
    Meyskens, FL
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2003, 12 (11) : 1280S - 1280S
  • [26] The combination of the selective cyclooxygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second-line therapy for non-small cell lung cancer: A phase II study with biological correlates
    Gasparini, G
    Meo, S
    Comella, G
    Stani, SC
    Mariani, L
    Gamucci, T
    Avallone, A
    Lo Vullo, S
    Mansueto, G
    Bonginelli, P
    Gattuso, D
    Gion, M
    CANCER JOURNAL, 2005, 11 (03): : 209 - 216
  • [27] Histone deacetylases as new therapeutical targets for the treatment of Non-Melanoma Skin Cancer: results of phase I/IIa trial with topical DAC060
    Botti, Elisabetta
    Mercurio, Ciro
    Spallone, Giulia
    Di Stefani, Alessandro
    Gabellini, Massimo
    Orlandi, Augusto
    Chimenti, Sergio
    Minucci, Saverio
    Costanzo, Antonio
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2011, 131 : S46 - S46
  • [28] Phase II trial of carboplatin plus docetaxel combined with a selective cyclooxygenase-2 inhibitor (meloxicam) in first-line treatment of patients with advanced unresectable non-small cell lung cancer: anti-tumor effect and cyclooxygenase-2 expression
    Sekine, Satoko
    Oshima, Kengo
    Ishida, Takashi
    Oizumi, Satoshi
    Yokouchi, Hiroshi
    Yamazaki, Koichi
    Sukoh, Noriaki
    Ogura, Shigeaki
    Munakata, Mitsuru
    Isobe, Hiroshi
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S455 - S455
  • [29] A Phase Ⅱ Clinical Trial of Celecoxib Combined with Platinum-Based Regimen as First-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer Patients with Cyclooxygenase-2 Positive Expression
    Jun Zhao
    Chinese Journal of Cancer Research, 2009, 21 (01) : 1 - 12
  • [30] Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC)
    Gadgeel, Shirish M.
    Ruckdeschel, John C.
    Heath, Elisabeth I.
    Heilbrun, Lance K.
    Venkatramanamoorthy, Raghu
    Wozniak, Antoinette
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (04) : 299 - 305
12345